is immune-based and includes ipilimumab and interleukin-2 (IL-2), which have activity regardless of BRAF mutational status. Ipilimumab is a monoclonal antibody that blocks the immune checkpoint CTLA-4 (cytotoxic T-lymphocyte antigen 4) and has
Search Results
Douglas B. Johnson and Jeffrey A. Sosman
Daniel G. Coit and Anthony J. Olszanski
However, interest has turned to new drug classes, including anti-CTLA4 antibodies and inhibitors of BRAF, which exploit the propensity of immune recognition and inhibition of signal-transduced growth/proliferation, respectively. The BRAF “driver” mutation
Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt, Sakshi Malhotra, Apar Kishor Ganti, and Ketki K. Tendulkar
. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series . Endocr Pract 2012 ; 18 : 351 – 355 . 14. Yang JC Hughes M Kammula U . Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic
Kelly G. Paulson and Shailender Bhatia
: Ipilimumab (anti-CTLA4) has been used off-label in 5 patients with 2 successes. 54 Prospective trials of ipilimumab (either alone or in combination with radiation and/or nivolumab) are ongoing ( ClinicalTrials.gov identifiers: NCT03071406, NCT02488759) and
Douglas B. Johnson, Riyue Bao, Kristin K. Ancell, Anthony B. Daniels, Deborah Wallace, Jeffrey A. Sosman, and Jason J. Luke
-third of UMs will ultimately metastasize. 1 , 2 In the setting of metastatic disease, treatment options are limited and prognosis is poor. Immunotherapies, specifically those targeting PD-1 and cytotoxic T-lymphocyte antigen-4 (CTLA-4), have transformed
Jarushka Naidoo
Another study showed that the microbiome is predictive not only of response but also of toxicity: the investigators demonstrated that the presence of a certain species of microbe may be protective against the development of colitis from anti–CTLA-4 therapy
John A. Thompson
/unresectable melanoma. Ipilimumab is a human monoclonal antibody that binds to the cytotoxic T-lymphocyte antigen-4 (CTLA-4), blocks the corresponding immune checkpoint signal, and results in lymphocyte proliferation and immune stimulation. The FDA approved ipilimumab
Presenter: Robert I. Haddad
-1 and CTLA-4 pathways, comparing combination nivolumab + ipilimumab to the EXTREME regimen as first-line treatment in patients with recurrent/metastatic HNSCC ( ClinicalTrials.gov identifier: NCT02741570). Patients with PD-L1–positive tumors appear
Presenter: Robin Kate Kelley
selection of ICIs (either as monotherapy or in combination) have received accelerated FDA approvals in the second-line setting based on earlier levels of data in phase I/II studies: nivolumab, 13 pembrolizumab, 14 and nivolumab in combination with the CTLA
Presenter: Arlene O. Siefker-Radtke
immune-related toxicities after treatment with the CTLA-4 antibody ipilimumab in combination with gemcitabine + cisplatin. 5 This chemoimmunotherapy regimen did not appear to impact OS. Furthermore, another study suggested that chemotherapy may promote